ADMA Biologics Newsroom

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28

Futu NewsDec 18 01:32

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating

Futu NewsDec 3 15:32

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24

Futu NewsNov 20 20:34

Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24

Futu NewsNov 9 09:31

ADMA Biologics Is Maintained at Strong Buy by Raymond James

Dow JonesNov 9 01:46

ADMA Biologics Analyst Ratings

BenzingaNov 9 01:36

H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26

Futu NewsNov 8 20:31

Key Takeaways From ADMA Biologics Analyst Ratings

BenzingaOct 14 20:02

H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18

Futu NewsOct 14 18:31

Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance

TipRanksOct 14 18:17

ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities

TipRanksOct 14 15:00

ADMA Biologics Analyst Ratings

BenzingaSep 20 23:12

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

BenzingaSep 20 23:12

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $18

BenzingaAug 12 18:54

Buy Rating Affirmed for ADMA Biologics Amid Strong Financial Performance and Promising R&D Prospects

TipRanksAug 12 18:30

ADMA Biologics Analyst Ratings

BenzingaAug 9 23:27

Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)

TipRanksAug 9 20:48

Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating

MT NewswiresJul 9 21:37

ADMA Biologics Analyst Ratings

BenzingaJul 9 21:24

Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $15

BenzingaJul 9 21:24